Provided by Tiger Fintech (Singapore) Pte. Ltd.

Salarius Pharmaceuticals Inc

0.6300
+0.03075.12%
Post-market: 0.64390.0139+2.21%19:58 EDT
Volume:4.07M
Turnover:2.71M
Market Cap:1.34M
PE:-0.14
High:0.7000
Open:0.6683
Low:0.5876
Close:0.5993
Loading ...

Salarius Pharmaceuticals Inc. Raises $3.8 Million Through Issuance of 5.5 Million Shares Under Equity Line of Credit

Reuters
·
Yesterday

Salarius Pharmaceuticals Amends Merger Agreement with Decoy Therapeutics to Modify Preferred Stock Conversion Terms

Reuters
·
30 Jul

Why is Penny Stock Salarius Pharmaceuticals (SLRX) Up 182% Today?

TIPRANKS
·
29 Jul

US Stocks Mixed; Procter & Gamble Posts Upbeat Earnings

Benzinga
·
29 Jul

Salarius Pharmaceuticals Updates Merger Agreement with Decoy Therapeutics, Introducing Series B Preferred Stock for Note Exchange

Reuters
·
21 Jul

Press Release: Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Dow Jones
·
09 Jul

Salarius Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance Amid Delisting Concerns

Reuters
·
17 Jun

Salarius Pharmaceuticals Updates Merger Agreement with Decoy Therapeutics Amid Market Changes

Reuters
·
11 Jun

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

GlobeNewswire
·
16 Apr

BRIEF-Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces Its Novel Inhibitors Show Promising In Silico Activity Against Measles And Related Viruses

Reuters
·
26 Mar

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Announces its Novel Inhibitors Show Promising In Silico Activity Against Measles and Related Viruses

GlobeNewswire
·
26 Mar

Salarius Pharmaceuticals 2024 EPS $(5.79) vs $(30.74) YoY

Benzinga
·
24 Mar

Press Release: Salarius Pharmaceuticals Reports 2024 Financial Results and Provides Business Update

Dow Jones
·
24 Mar

Salarius Pharmaceuticals Announces Patient Enrollment to Resume in Investigator-initiated Phase 1/2 Clinical Trial Using Seclidemstat with Azacitidine to Treat Hematologic Cancers

GlobeNewswire
·
03 Feb